CIP
KNSA icon

Cornerstone Investment Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Cornerstone Investment Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,319
Closed -$233K – 272
2024
Q3 		$233K Buy
+9,319
New +$227K 0.01% 153
2023
Q3 		– Sell
-10,474
Closed -$147K – 221
2023
Q2 		$147K Buy
+10,474
New +$140K 0.01% 191

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cornerstone Investment Partners's KNSA Position: Q4 2024 in Review

Cornerstone Investment Partners sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2024, closing a stake of 9,319 shares — an estimated $233K sold.

Cornerstone Investment Partners first reported a position in KNSA in Q2 2023 and held it in 2 quarters. The position peaked at $233K in Q3 2024. 160 funds tracked by Wall St. Rank hold KNSA as of Q4 2024.

  • Cornerstone Investment Partners reported no remaining Kiniksa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cornerstone Investment Partners sold 9,319 Kiniksa Pharmaceuticals shares in Q4 2024, an estimated $233K.
  • Cornerstone Investment Partners first reported a position in Kiniksa Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Cornerstone Investment Partners's Kiniksa Pharmaceuticals position peaked at $233K in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2024.

Based on Cornerstone Investment Partners's 13F filing for Q4 2024, filed 6 Feb 2025.